目的 評價沙丁胺醇與硫酸鎂聯(lián)合霧化吸入治療支氣管哮喘的臨床效果。方法 選取科右前旗人民醫(yī)院2013年3月到2015年3月門診確認的100名支氣管哮喘的患者為研究對象,按照隨機以及結(jié)合患者意愿的方法分為觀察組與對照組。兩組患者在年齡、性別、病情等方面差異無統(tǒng)計學(xué)意義。對照組給予沙丁胺醇霧化吸入治療,觀察組給予沙丁胺醇與硫酸鎂聯(lián)合霧化吸入治療。通過檢測患者的肺功能恢復(fù)情況,第一秒用力呼氣量(FEV1)、最大呼氣流量(PEF),評價此種方法的臨床效果以及安全性。結(jié)果 兩組患者在治療后,FEV1與PEF相對比激發(fā)值均有提高(P<0.05);觀察組的患者的FEV1與PEF的上升率高于對照組(P<0.05),且恢復(fù)后的FEV1與PEF值高于對照組。在20 min后,患者的肺功能值恢復(fù)至正常值。在觀察組中出現(xiàn)1(2%)例副作用的患者。結(jié)論 沙丁胺醇與硫酸鎂霧化吸入對于支氣管哮喘的治療有積極的臨床治療效果,但是對于進一步的使用,需要進行更深的研究與探索,減少其對患者的副作用。

Objective To evaluation the clinical efficacy of salbutanmol and magnesium sulfate aerosol inhalation in treatment of bronchial asthma. Methods 100 cases with bronchial asthma in our hospital were chosen, who were randomly divided into the observation group and control group according to patients will. The age, sex, disease of two groups had no significant difference. The control group were given salbutamol aerosol inhalation, he observation group were given salbutamol and magnesium sulfate combined with atomization inhalation treatment. The lung function recovery of FEV1 (force dexpiratory volune), PEF (peak expiratory flow) of patients were detected, the clinical efficacy and safety of the method were evaluated. Results Compared with stimulation value, the FEV1 and PEF after treatment were all improved (P < 0.05), the escalating rate of the observation group FEV1 and PEF were higher than the control group (P < 0.05), the EFV1 and PEF after recovery were higher than the control group. The lung function after treatment for 20 min were back to normal. The observation group had one patient with adverse reaction (2%). Conclusion The salbutamol and magnesium sulfate aerosol inhalation in treatment of bronchial asthma had positive clinical treatment efficacy, while in the further use, which need further research and exploration and reduce the patient's adverse reaction.